• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?

    7/18/24 2:05:28 PM ET
    $AA
    $ABT
    $ALK
    $BX
    Aluminum
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AA alert in real time by email

    It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels last seen in late April.

    Both the S&P 500 and the Nasdaq 100 indices declined by 0.6%, while the Dow Jones Industrial Average fell 0.7%, potentially ending a streak of six consecutive positive sessions.

    Small-cap stocks also succumbed to the broader negative sentiment, with the Russell 2000 index dropping 0.7%.

    Chicago Fed President Austan Goolsbee, a known “dove” on the board, expressed optimism about progress on inflation and the U.S. economy’s resilience in avoiding a recession. He did not commit to a potential rate cut in September.

    Following Wednesday’s sell-off triggered by concerns over increased U.S. chip export restrictions to China, semiconductor stocks remained broadly weaker, with the iShares Semiconductor ETF (NYSE:SOXX) down by 0.6%. Despite this, Nvidia Corp. (NASDAQ:NVDA) defied the trend, rising 1.8%.

    Significant volatility erupted in the health care sector, particularly within the weight loss drug industry. The market duopoly of Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) face heightened competitive threats from Pfizer Inc. (NYSE:PFE) and Roche Holding Ltd (OTCPK: RHHBY), both of which recently announced developments to enter this lucrative market.

    Shares of Eli Lilly plunged 5.6%, marking their worst session since mid-March 2021, while Novo Nordisk shares dropped 5%, their worst performance since August 2022.

    On the economic data front, jobless claims rose more than expected last week and continuing claims reached their highest level since November 2021, indicating a cooling trend in the labor market.

    The U.S. dollar acted as a safe haven, rising 0.3%, while Treasury yields inched higher across the curve. The European Central Bank kept interest rates unchanged, as expected, keeping the door open for September.

    In commodities, growth-sensitive copper tumbled over 3%, hitting its lowest level since mid-April. Silver eased by 0.9% and gold remained flat. Oil prices slipped 0.3%, while natural gas surged over 4%, nearly recouping Wednesday’s sharp losses following a weaker-than-expected buildup in inventories last week.

    Bitcoin (CRYPTO: BTC) edged 0.4% lower, eyeing a second consecutive negative close.

    Thursday’s Performance In Major US Indices, ETFs

    Major IndicesPrice1-day %chg
    Nasdaq 10019,687.70-0.6%
    S&P 5005,556.41-0.6%
    Dow Jones40,929.46-0.7%
    Russell 20002,220.63-0.7%
    Updated at 12:55 p.m. ET

    According to Benzinga pro data:

    • The SPDR S&P 500 ETF Trust (NYSE:SPY) was 0.6% lower to $553.74.
    • The SPDR Dow Jones Industrial Average (NYSE:DIA) fell by 0.7% to $409.10.
    • The tech-heavy Invesco QQQ Trust (ARCA: QQQ) fell 0.5% to $479.14.
    • Sector-wise, the Energy Select Sector SPDR Fund (NYSE:XLE) outperformed, up by 1%, while the Health Care Select Sector SPDR Fund (NYSE:XLV) lagged, down 1.5%.

    Thursday’s Market Movers

    • Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) fell 0.9% despite reporting stronger-than-expected results last quarter.
    • Other stocks reacting to corporate earnings were Abbott Laboratories (NYSE:ABT), down 3.5%, Alcoa Corporation (NYSE:AA), down 1%, SL Green Realty Corp. (NYSE:SLG) down 2.5%, Kinder Morgan, Inc. (NYSE:KMI), up 3.8%, Domino’s Pizza, Inc. (NYSE:DPZ), down 13%, Blackstone Inc. (NYSE:BX), up 2.6%, Marsh & McLennan Companies, Inc. (NYSE:MMC), down 1%, Alaska Air Group, Inc. (NYSE:ALK), down over 5%, Cintas Corp. (NASDAQ:CTAS), up over 6%, D.R. Horton, Inc. (NYSE:DHI), up 13%, Virtu Financial Inc. (NASDAQ:VIRT), up 18% and Novartis AG (NYSE:NVS), down 4.4%.
    • Companies reporting after the close include Netflix, Inc. (NASDAQ:NFLX) and Intuitive Surgical, Inc. (NASDAQ:ISRG).

    Read now:

    • Project 2025 Wants To Radically Change US Tax Policy: Would You Pay More Or Less In Taxes?

    Photo via Shutterstock.

    Get the next $AA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AA
    $ABT
    $ALK
    $BX

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    2/23/2026Buy → Hold
    Deutsche Bank
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Cintas Corporation
    $CTAS
    2/17/2026$215.00Neutral
    BofA Securities
    Taiwan Semiconductor Manufacturing Company Ltd.
    $TSM
    2/13/2026$450.00Buy
    DA Davidson
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Novo Nordisk A/S
    $NVO
    2/12/2026Underperform → Hold
    Jefferies
    Nokia Corporation Sponsored
    $NOK
    2/9/2026$8.00Overweight
    Morgan Stanley
    More analyst ratings

    $AA
    $ABT
    $ALK
    $BX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-President & Co-COO Molluso Joseph sold $7,776,420 worth of shares (200,000 units at $38.88), decreasing direct ownership by 38% to 326,585 units (SEC Form 4)

    4 - Virtu Financial, Inc. (0001592386) (Issuer)

    2/20/26 5:28:10 PM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    EVP AND CCO Harrison Andrew R sold $311,487 worth of shares (5,500 units at $56.63), decreasing direct ownership by 15% to 30,828 units (SEC Form 4)

    4 - ALASKA AIR GROUP, INC. (0000766421) (Issuer)

    2/20/26 5:19:37 PM ET
    $ALK
    Air Freight/Delivery Services
    Consumer Discretionary

    EVP AND CFO Tackett Shane R sold $1,371,533 worth of shares (24,000 units at $57.15), decreasing direct ownership by 36% to 43,377 units (SEC Form 4)

    4 - ALASKA AIR GROUP, INC. (0000766421) (Issuer)

    2/20/26 5:17:13 PM ET
    $ALK
    Air Freight/Delivery Services
    Consumer Discretionary

    $AA
    $ABT
    $ALK
    $BX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novo Nordisk A/S downgraded by Deutsche Bank

    Deutsche Bank downgraded Novo Nordisk A/S from Buy to Hold

    2/23/26 8:43:42 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ABT
    $ALK
    $BX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Porat Ruth bought $68,553 worth of shares (525 units at $130.68), increasing direct ownership by 1% to 39,502 units (SEC Form 4)

    4 - Blackstone Inc. (0001393818) (Issuer)

    2/20/26 4:12:44 PM ET
    $BX
    Investment Managers
    Finance

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith William A bought $89,236 worth of Class P Common Stock (3,000 units at $29.75), increasing direct ownership by 11% to 31,087 units (SEC Form 4)

    4 - KINDER MORGAN, INC. (0001506307) (Issuer)

    2/3/26 4:53:53 PM ET
    $KMI
    Natural Gas Distribution
    Utilities

    $AA
    $ABT
    $ALK
    $BX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

    Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and

    2/23/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

    Blackstone Life Sciences ("BXLS") today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia ("AML"). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance a portion of the ongoing and future clinical trials of bleximenib in AML. This is the first time that BXLS and Johnson & Johnson have entered into a co-funding agreement. "We believe that bleximenib's promising clinical data, combined

    2/23/26 7:00:00 AM ET
    $BX
    Investment Managers
    Finance

    $AA
    $ABT
    $ALK
    $BX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 1, 2024 - FDA Roundup: November 1, 2024

    For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

    11/1/24 3:18:19 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ABT
    $ALK
    $BX
    SEC Filings

    View All

    SEC Form 424B3 filed by Abbott Laboratories

    424B3 - ABBOTT LABORATORIES (0000001800) (Filer)

    2/23/26 9:31:03 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Abbott Laboratories

    S-3ASR - ABBOTT LABORATORIES (0000001800) (Filer)

    2/23/26 8:55:31 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    2/23/26 8:19:22 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ABT
    $ALK
    $BX
    Leadership Updates

    Live Leadership Updates

    View All

    Ben Brookman promoted to Vice President of Real Estate and Airport Affairs for Alaska Airlines

    With 17 years in the airline industry, Brookman will lead Alaska's global real estate strategy, and investments across all airports. SEATTLE, Feb. 12, 2026 /PRNewswire/ -- Ben Brookman has been promoted to Vice President of Real Estate and Airport Affairs at Alaska Airlines. The growing real estate portfolio is another step in Alaska's strategic vision to connect guests to the world with a remarkable travel experience rooted in safety, care and performance. Brookman will lead the team responsible for Alaska's strategy for airport access, infrastructure and corporate real esta

    2/12/26 12:45:00 PM ET
    $ALK
    Air Freight/Delivery Services
    Consumer Discretionary

    Alaska Airlines and Hawaiian Airlines introduce spring menus featuring regional favorites and chef-led dining

    Designed for the season, Alaska Airlines new spring menu celebrates Pacific Northwest partnerships with comforting favorites like Beecher's Mac & Cheese, balanced by fresh, seasonal and plant-forward offeringsHawaiian Airlines is refreshing its domestic First Class dining with new menus by Chef Robynne Maii and Chef Wade Ueoka bringing thoughtfully crafted, island-inspired comfort on flights between Hawai'i and the U.S. ContinentSEATTLE, Feb. 11, 2026 /PRNewswire/ --  Alaska Airlines and Hawaiian Airlines are welcoming spring with the launch of new seasonal menus, bringing fresh flavors, thoughtful sourcing and chef-inspired dishes to guests.

    2/11/26 8:00:00 AM ET
    $ALK
    Air Freight/Delivery Services
    Consumer Discretionary

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ABT
    $ALK
    $BX
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Domino's Pizza® Announces Fourth Quarter and Fiscal 2025 Financial Results

    Global retail sales growth (excluding foreign currency impact) of 4.9% for the fourth quarter; 5.4% growth for fiscal 2025U.S. same store sales growth of 3.7% for the fourth quarter; 3.0% growth for fiscal 2025International same store sales growth (excluding foreign currency impact) of 0.7% for the fourth quarter; 1.9% growth for fiscal 2025Global net store growth of 392 for the fourth quarter; global net store growth of 776 for fiscal 2025Income from operations increased 8.0% for the fourth quarter; 8.5% for fiscal 2025(Income from operations increased 7.3% and 8.6% for the fourth quarter and fiscal 2025, respectively, excluding the $1.9 million positive impact for fourth quarter and the $0

    2/23/26 6:05:00 AM ET
    $DPZ
    Food Distributors
    Consumer Discretionary

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ABT
    $ALK
    $BX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alcoa Corporation

    SC 13G - Alcoa Corp (0001675149) (Subject)

    11/14/24 4:14:03 PM ET
    $AA
    Aluminum
    Industrials

    Amendment: SEC Form SC 13G/A filed by Domino's Pizza Inc

    SC 13G/A - DOMINOS PIZZA INC (0001286681) (Subject)

    11/14/24 1:28:31 PM ET
    $DPZ
    Food Distributors
    Consumer Discretionary

    SEC Form SC 13G filed by Alcoa Corporation

    SC 13G - Alcoa Corp (0001675149) (Subject)

    11/14/24 1:18:12 PM ET
    $AA
    Aluminum
    Industrials